Eight cases of ecstasy related acute liver damage referred to a specialised liver unit are described. Two patients presented after collapse within (Gut 1996; 38: 454-458) 
The social use of 3,4 methyldioxymethamphetamine (MDMA), otherwise known as 'ecstasy', and other drugs with similar effects such as 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxyethamphetamine (MDEA) is widespread in the United Kingdom and Europe. Ecstasy is taken at 'rave-parties' for its amphetamine-like stimulatory effect allowing users to dance for prolonged periods with increased energy and reduced awareness of fatigue. Publications to date have brought attention to patients collapsing with hyperthermia complicated with disseminated intravascular coagulation and rhabdomyolysis.' 2 Other complications reported include cerebral haemorrhage, hyponatraemia, and cardiac arrhythmias.3-5 Seven cases of ecstasy related hepatotoxicity were reported in a study of telephone referrals to The National Poisons Information Service, two of which were subsequently described in more detail in correspondence columns as single cases with liver dysfunction.6-8 Six further cases have been described as single case reports9 12 making 13 possible cases in total (Table) .
This paper describes eight patients referred to a single centre with evidence of acute liver damage temporally related to the ingestion of ecstasy, two cases presenting with hyperthermia and six with an acute hepatitic illness. Five patients developed encephalopathy and severe coagulopathy sufficient to merit listing for transplantation. pressure. Despite treatment with broad spectrum antibiotics and intravenous antifungal agents she became profoundly septic with a cardiac output of 18 1/min and died before a donor organ became available. platelet count increased from 37 to 219 X 1 09. Serum bilirubin peaked at 287 pumoYl on day 3. Having required ventilation for six days he was discharged home on day 15, the serum bilirubin having fallen to 56 pumol/l. [Lmol/l, alkaline phosphatase 173 IU/1, AST 1191 IU/1, and GGT 169 IU/l. Over a three day period he required 10% dextrose to maintain his blood sugar. All known causes of acute hepatitis were excluded and an ultrasound was unremarkable. Liver biopsy showed ballooning of hepatocytes and some acidophilic bodies. Both the sinusoids and portal tracts showed mild to moderate inflammatory infiltrates consisting of lymphocytes, neutrophils, and eosinophils. Cholestasis was evident and overall findings were consistent with a drug related hepatitis (Fig 3) . Case 8 A 24 year old woman presented to casualty in grade III encephalopathy having recently arrived in England after a two month holiday in the Caribbean. She had been seen one week earlier at a local hospital with a non-specific illness and jaundice. There was no hepatosplenomegaly and investigations showed a white cell count of 18 X 109/1, INR >15, urea 0.5 mmol/l, creatinine 52 ,umol/l, glucose 1.2 mmol/l, albumin 37 g/l, bilirubin 407 ,umol/l, alkaline phosphatase 295 lUl1, AST 721 lU/1, GGT 123 IU/1. Fulfilling criteria for transplantation she was placed on the urgent list and a liver became available after 48 hours. Because of a mismatch in size between donor and recipient she received a reduced graft. In the postoperative phase there were no episodes of rejection and she was discharged home well after five weeks. All tests for known causes of acute liver failure were negative and in a subsequent outpatient visit she admitted to having taken two to four tablets of ecstasy in the six weeks prior to her admission. Histological examination showed a small shrunken liver with diffusely collapsed parenchyma. Com Of the remaining six cases, four had severe liver damage progressing to acute liver failure in the absence of a hyperthermic episode. All other causes of acute liver failure were excluded including hepatitis A, B, C, E, herpes viruses, autoimmune disease, Wilsons's disease, and other potentially hepatotoxic drugs. The illness was characterised by malaise, nausea and vomiting, hyperbilirubinaemia, and progressive coagulopathy followed by the development of encephalopathy and sepsis. One patient survived after transplantation, one died of cerebral oedema before a donor organ became available, and the other two died as a result of continuing sepsis between three and four weeks post-transplantation. The survival rate after transplantation (one of three, 33%) in this group is similar to that of other reported series of drug induced acute liver failure and most probably reflects the duration of illness before transplantation and a combination of poor nutrition and sepsis. The remaining two cases presented with a milder illness consistent with a less severe process of hepatic damage and recovered spontaneously over a period of three weeks without developing severe coagulopathy or encephalopathy. In those cases with acute liver damage without heatstroke, the development of coagulopathy may lead to further deterioration and referral to a centre with facilities for liver transplantation should be made earlier rather than later as once encephalopathy has developed, deterioration beyond this is rapid. However, to date there is only one case noted with a successful result after transplantation. 6 The mechanism of MDMA induced hepatic injury is unclear but a spectrum of severity seems to exist as assessed with histological changes varying from a mild to moderate lobular hepatitis to features of massive hepatic parenchymal collapse with areas of nodular regeneration. The severity of liver damage does not seem to correlate with either the amount or frequency of MDMA ingested suggesting an idiosyncratic type of reaction. Individual susceptibility to MDMA hepatotoxicity is possible as a single case of recurrent hepatitis after exposure has been reported.7 Except after an acute collapse with hyperthermia, MDMA will not be detectable in the urine or blood because of the short half life of the drug and the usual interval between ingestion and presentation. It is therefore important to include a comprehensive drug history, both oral and intravenous, in young patients presenting with an unexplained hepatitis and care should be exercised in follow up with the risks of progression to acute liver failure.
